Vascular Access Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Vascular Access Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The global vascular access devices market is expected to register a CAGR of nearly 6.5% during the forecast period (2022-2027).

The demand for medical equipment has been impacted by COVID-19 in numerous ways. While the demand for the devices used to treat COVID-19 patients in intensive care has increased, other devices have suffered as a result of delayed or canceled treatments. According to the study titled “The impact of the COVID-19 pandemic on vascular surgery: Health care systems, economic, and clinical implications” published in the National Library of Medicine in July 2021, in ambulatory care and outpatient clinics, 89.2% of vascular surgeons reported changes to their practice, including fewer hours (71%) and the use of telehealth services (81.1%). Clinical volume dropped by 96.5%, surgical volume dropped by 71.7%, and the daily number of inpatient consultations dropped to just 1.81 per day. Thus, the decline in surgical volume significantly hampers the market during COVID-19. Moreover, according to the study titled "Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals" published in May 2022, patients who have the 2019 coronavirus disease (COVID-19) are at a high risk of venous thromboembolism (VTE). 10.0% of COVID-19 hospitalized patients in Michigan who had vascular access devices had a VTE incident, compared to 4.3% of those without these devices. Thus, vascular access devices increased the risk of VTE in COVID-19 patients hence it has hampered the market growth during the COVID-19 pandemic.

Over the past decade, there has been a rise in the prevalence of several chronic diseases that need vascular access treatment. Some of the major chronic diseases include cancer, kidney failure, and heart diseases, among others. Along with these, there are several lifestyle disorders relating to chronic and non-communicable disease conditions, such as hypertension, diabetes, obesity, and depression, among others, which need critical care during their hospitalization. According to GLOBOCAN 2020, the new cancer cases that were diagnosed accounted for 19,292,789 in 2020 globally, with 9,958,133 deaths due to cancer. Moreover, as per the same source, among all cancers, breast cancer accounted for 2,261,419 new cancer cases, followed by lung cancer with 2,206,771 new cases, prostate cancer with 1,414,259, and colon cancer with 1,148,515 new cases in 2020. Additionally, according to World Health Organization (WHO) data published in April 2021, chronic diseases are expected to kill 41 million people each year, equivalent to 71% of all deaths globally. Also, 77% of mortality in low- and middle-income nations is attributable to chronic diseases. Additionally, as per the same source, most of the chronic illness mortality, or around 17.9 million people per year, is caused by cardiovascular disorders, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). With the increase in the number of cancer cases, the demand for vascular access devices is expected to increase over the forecast period.

The vascular access devices demand is growing in pediatrics for several indications. For instance, according to the study titled "Pediatric central venous access devices: practice, performance, and costs" published in the pediatric Research in February 2022, the majority of pediatric health disciplines employ central venous access devices (CVADs) as a standard tool for a variety of therapies, including lifelong parenteral feeding for gut enteropathies and the delivery of antibiotics for persistent osteomyelitis. Thus, increasing use of the vascular access devices in the pediatric discipline is anticipated to boost the market growth over the forecast period.

With the rising prevalence of chronic diseases and lifestyle disorders, vascular access procedures are increasingly being used for intravenous antibiotic treatment, long intravenous nutritional support, and drawing of blood samples. Hence this is expected to draw the attention of several multinational medical devices companies to invest and launch new products, thus, acting as one of the major drivers for this market. For instance, in June 2021, medK launched a needle-free solution for vascular access. The needle-free connection tends to offer access to the fluid lines, thereby reducing the risk of needle sticks. Additionally, in May 2022, Shockwave Medical announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both CE mark and the United States Food and Drug Administration (FDA) clearance.

However, stringent regulation and product recall, and risks associated with catheter usage restraint the market growth over the forecast period.

Key Market TrendsAdministration of Drugs is Expected to Show a Large Share in the Application Segment

The drug administration segment is estimated to account for the largest share of the market as the growth of the drug administration segment is attributed to the high usage of vascular access devices for drug administration for the treatment of infections, cancer, and other diseases. Catheters are used for a variety of functions, including administering drugs, drawing blood, and specialized treatments like hemodialysis. Vascular access catheters can be inserted either peripherally in a patient’s arm or centrally, such as in the patient’s jugular. According to Cystic Fibrosis Foundation in November 2021, vascular access devices make it possible to repeatedly and continuously get access to the bloodstream for the administration of medications, such as intravenous (IV) antibiotics.

Furthermore, according to the study titled "Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomized controlled trial" published in the National Library of Medicine in July 2021, Systemic anticancer treatment (SACT) is administered in a central vein using Hickman-type tunneled catheters (Hickman), peripherally inserted central catheters (PICCs), and completely implanted ports (PORTs). Compared to Hickman and PICCs, PORTs are safer and more effective for patients receiving SACT. Thus, the availability of the various vascular access devices as well as their effectiveness over the other devices supports the segment growth.

As per the European Kidney Alliance, in 2021, 700–800 million people worldwide has chronic kidney disease. It is predicted that by 2040, chronic kidney disease would be the fifth leading cause of mortality worldwide. Because patients with chronic renal disorders need central venous access, the rise in the prevalence of chronic kidney disease has led to the segment's robust growth.

Thus, owing to above-mentioned factors it is expected to drive segment growth over the forecast period.

North America to Dominate the Vascular Access Devices Market Over the Forecast Period

The North America segment is expected to account for the largest share of the market that can primarily be attributed to the high prevalence of cardiovascular diseases in the United States an increase in the number of cancers cases; and an increase in research and clinical trials for vascular access devices. According to the estimates of the American Cancer Society, in 2022, it is expected that 79,000 new instances of kidney cancer are likely to be diagnosed in the United States, including 50,290 cases in males and 28,710 cases in women. The top 10 malignancies for both men and women include kidney cancer. Men have about 1 in 46-lifetime risk of having kidney cancer (2.02% ). For women, the lifetime risk is approximately 1 in 80. (1.03% ). Additionally, in many cases of end-stage renal disease (ESRD), dialysis patients are treated via a catheter, which is performed in an outpatient setting, thus, reducing the hospitalization of ESRD patients by allowing the non-emergency interventional procedures to be carried out.

The factors, such as government guidelines for the regulation of medical devices by the company, better healthcare infrastructure, etc., play a key role in increasing the business and in the launching of new products by multinational companies, thereby, contributing the market growth. For instance, in September 2021, Cardiovascular Systems, Inc. (CSI) announced the commercial launch of the company’s ViperCross peripheral support catheter, which recently received Food and Drug Administration 510(k) clearance. Additionally, market participants frequently introduce new products and use a variety of growth tactics in their segments, which is likely to spur market expansion. For instance, in September 2021, Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy systems will be incorporated into Abbott's existing endovascular product portfolio.

Therefore, the growing demand for technological advancements is expected to drive the market shortly.

Competitive Landscape

The vascular access devices market is highly competitive and there are several small to mid-sized companies that are posing strong competition to gain the market share. However, few companies that are doing a good business in the market include B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, NIPRO Medical Corporation, and Fresenius Medical Care.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.